Show simple item record

AuthorCrovella, Sergio
AuthorRevelant, Alberto
AuthorMuraro, Elena
AuthorMoura, Ronald Rodrigues
AuthorBrandão, Lucas
AuthorTrovò, Marco
AuthorSteffan, Agostino
AuthorZacchi, Paola
AuthorZabucchi, Giuliano
AuthorMinatel, Emilio
AuthorBorelli, Violetta
Available date2022-01-25T06:08:39Z
Publication Date2021-12-22
Publication NameFrontiers in Oncology
Identifierhttp://dx.doi.org/10.3389/fonc.2021.784081
CitationCrovella S, Revelant A, Muraro E, Moura RR, Brandão L, Trovò M, Steffan A, Zacchi P, Zabucchi G, Minatel E and Borelli V (2021) Biological Pathways Associated With the Development of Pulmonary Toxicities in Mesothelioma Patients Treated With Radical Hemithoracic Radiation Therapy: A Preliminary Study. Front. Oncol. 11:784081. doi: 10.3389/fonc.2021.784081
Identifier784081
URIhttp://hdl.handle.net/10576/25909
AbstractRadical hemithoracic radiotherapy (RHR), after lung-sparing surgery, has recently become a concrete therapeutic option for malignant pleural mesothelioma (MPM), an asbestos-related, highly aggressive tumor with increasing incidence and poor prognosis. Although the toxicity associated to this treatment has been reduced, it is still not negligible and must be considered when treating patients. Genetic factors appear to play a role determining radiotherapy toxicity. The aim of this study is the identification of biological pathways, retrieved through whole exome sequencing (WES), possibly associated to the development of lung adverse effects in MPM patients treated with RHR. The study included individuals with MPM, treated with lung-sparing surgery and chemotherapy, followed by RHR with curative intent, and followed up prospectively for development of pulmonary toxicity. Due to the strong impact of grade 3 pulmonary toxicities on the quality of life, compared with less serious adverse events, for genetic analyses, patients were divided into a none or tolerable pulmonary toxicity (NoSTox) group (grade ≤2) and a severe pulmonary toxicity (STox) group (grade = 3). Variant enrichment analysis allowed us to identify different pathway signatures characterizing NoSTox and Stox patients, allowing to formulate hypotheses on the protection from side effects derived from radiotherapy as well as factors predisposing to a worst response to the treatment. Our findings, being aware of the small number of patients analyzed, could be considered a starting point for the definition of a panel of pathways, possibly helpful in the management of MPM patients.
Languageen
PublisherFrontiers Media
Subjectmesothelioma
pulmonary toxicities
radical hemithoracic radiotherapy
thromboembolism
whole exome
TitleBiological Pathways Associated With the Development of Pulmonary Toxicities in Mesothelioma Patients Treated With Radical Hemithoracic Radiation Therapy: A Preliminary Study.
TypeArticle
Volume Number11
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record